India

 

With a population of more than one billion, India is the second largest country in the world, represents 16% of the global population, and the national average for life expectancy is only 65 years. India leads the world in the largest absolute burden of TB, ranks third for HIV (behind South Africa and Nigeria), and ranks second for diabetes. The country receives funding to support HIV/AIDS prevention, treatment and care programs under the US President's Emergency Plan for AIDS Relief (PEPFAR).

CCGHE partners with institutions in India tackle grave health issues on the front lines. LEARN ABOUT CCGHE-INDIA PARTNERSHIPS

 
CCGHE WORK IN INDIA

 

A5274: Reducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment Regimens

Post Date: 
2011-10-01
Country: 
Dr. Amita Gupta is Protocol Co-Vice Chair for this multinational clinical trial being conducted in Brazil, Haiti, Kenya, Malawi, Peru, South Africa, Uganda, Zambia, and Zimbabwe , and in India by the Baltimore-Washington-India Clinical Trials Unit, of which CCGHE is a member. People with HIV have a...

Cardiovascular risk in an HIV-infected population in India

Post Date: 
2017-07-03
Publication: 
Heart Asia
Country: 
Findings: HIV+ Indian patients who had cardiovascular disease at a younger age appear to be at imminent risk for morbidity.

MDR-TB Free: Monitoring Adverse Effects, Utilizing Resources Optimally, Knowing Resistance Patterns, and Treatment Strategy

Post Date: 
2017-03-24
Country: 
Purpose: To establish an observational cohort of MDR-TB cases and household contacts with accompanying biorepository at PD Hinduja National Hospital and Medical Research Centre Primary Objectives: Cohort A: To document participant outcomes including early treatment response, MDR-TB treatment-...

Evaluation of Longitudinal Blood Culture Isolates from BJ Medical College in Pune, India

Post Date: 
2014-06-16
Country: 
Antibiotic resistance is a serious global problem and is caused by multiple factors which have led to difficulty in the management of life-threatening, multi-drug resistant (MDR) bacterial bloodstream infections. The knowledge of antibiotic resistance patterns and availability of appropriate...

How Americans Benefit from Global Health Research

Post Date: 
2017-05-25
Presentation Location: 
Washington, DC
Country: 
Event & Convener: 
The Fogarty International Center: How Americans Benefit from Global Health Research Webinar, Research!America
Invited presenter. Live webinar with NIH Fogarty Director Roger Glass, and Johns Hopkins Desmond M. Tutu Professor of Public Health and Human Rights Chris Beyrer.

Characterization of Pulmonary and Extrapulmonary Tuberculosis Among Adult Patients Admitted to Sassoon General Hospital, Pune, India

Post Date: 
2011-09-27
Country: 
The diagnosis of pulmonary and extrapulmonary tuberculosis is usually made clinically. While confirmation from laboratory tests is sought, the sensitivity of such diagnostic tests is poor. TB diagnostics are still evolving and in resource poor settings diagnostic availabilty is limited. Therefore,...

A Prospective Study Evaluating the Burden of Cryptococcal Disease Among HIV-infected Population in Pune, India

Post Date: 
2011-01-06
Country: 
By 2008, 33.4 million people were living with HIV globally, with an estimated 2.3 million living in India, representing the third largest absolute burden of HIV globally. [1] The current statistics as summarized by National AIDS Control Organization (NACO) of India show that of the estimated 750,...

The Evaluation of Clinical Profile and Mortality of Children Admitted with Tuberculosis in Pediatric Intensive-Care Unit at Sassoon General Hospitals, Pune

Post Date: 
2016-10-27
Country: 
Tuberculosis (TB) is one of the most common causes of infection-related death globally. TB was declared global public health emergency in 1993 by World HealthOrganization (WHO). Mortality due to TB is increasing due to emergence of multidrug resistant (MDR) strains and HIV-TB co-infection,...

Understanding Quality of Life during and Loss to Follow-up from Drug-Resistant Tuberculosis Treatment in Pune, India

Post Date: 
2017-05-15
Country: 
This study will examine a) risk factors for loss to follow-up from DR-TB treatment, b) actively trace DR-TB patients lost to follow-up from treatment and c) establish a prospective observational cohort of MDR-TB, XDR-TB and DS-TB patients as well as healthy controls nested within ongoing RNTCP...

Pages

Subscribe to RSS - India